Slco1c1-2A-CreERT2

Nomenclature

C57BL/6Smoc-Slco1c1em1(2A-CreERT2)Smoc

Cat. NO.

NM-KI-200262

Strain State

Repository Live

Export PDF

Gene Summary

Gene Symbol
Slco1c1

Synonyms

Oatp2; Oatpf; OATP-F; OATP-14; Slc21a14

NCBI ID

58807

MGI ID

1889679

Ensembl ID

ENSMUSG00000030235

Pubmed

Slco1c1

Human Ortholog

SLCO1C1

Model Description

2A-CreERT2 expression cassette was knocked into the Slco1c1 gene stop codon site. Slco1c1 encodes a member of the organic anion transporter family. The encoded protein is a transmembrane receptor that mediates the sodium-independent uptake of thyroid hormones in brain tissues. This protein has particularly high affinity for the thyroid hormones thyroxine, tri-iodothyronine and reverse tri-iodothyronine. When Slco1c1-2A-CreERT2 mice are bred with mice containing loxP-flanked sequence, tamoxifen-inducible, Cre-mediated recombination will result in deletion of the floxed sequences in SLCO1C1 positive cells.
Research Application：Ischemic infarction

Validation Data

image.pngimage.png

Fig. 1 CreERT2-mediated recombination in the choroid plexus of Slco1c1-2A-CreERT2; Rosa26-tdTomato mice after tamoxifen treatment.

image.pngimage.png

Fig. 2 Labeling was also observed in the retina, muscles, but not in pituitary, heart, lungs, stomach, submandibular gland, brown fat, kidney, pancreas, small and large intestine, spleen, skin, ovaries and uterus.（For more information please contact: 400-728-0660.）

You may also like

Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute

On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.

Learn more
Workshop：Progress and Advances in Preclinical immuno-Oncology Research

SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.

Learn more